Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

Inclusion Criteria:

Confirmed diagnosis of any LC-FAOD sub-type. Diagnosis must be confirmed by results of acylcarnitine profiles, and/or mutation analysis obtained from medical records or equivalent documentation.
Willing and able to comply with all study procedures.
Willing and able to provide written informed consent after the nature of the study has been explained, and prior to any research-related procedures. For minors (<16 or<18 years of age, as defined by region) willing and able (if possible) to provide written assent and have a legally authorized representative willing and able to provide written informed consent after the nature of the study has been explained, and prior to any research-related procedures.
Female of child-bearing potential who become pregnant during the study will be invited to remain in the study. Pregnant females with LC-FAOD will be informed of the study and invited to enroll.
Pregnant females carrying affected fetus(es) with confirmed pre-natal diagnosis of LC-FAOD, will also be informed of the study and invited to enroll.

Exclusion Criteria:

Presence of a concurrent disease or condition that would interfere with study participation or affect patient's safety in the opinion of the Investigator.
Presence or history of any condition that, in the view of the Investigator, places the patient at high risk of not completing the study or would affect the interpretation of study results.